Company intelligence / Profile preview

Himalaya Therapeutics

Shanghai, Shanghai, Chinahimalayatherapeutics.com ↗

Ownership: Public · HMLA
Development stage: Phase 2

Overview

The company has multiple CAB antibodies in development, with two programs in Phase 2 clinical trials (Ozuriftamab vedotin and Mecbotamab vedotin) and two in Phase 1 (BA-3181 and BA3151). Their CAB technology creates antibodies that selectively bind to targets on tumor cells but not normal cells.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesAntibody-drug conjugates (ADCs)Bispecific T-cell Engagers (BiTEs)Bispecific antibodiesProbody drug conjugates
Industry: Biotech

Drug pipeline

4 assets

CAB-EGFR

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

BioAtla (licensed CAB technology from BioAtla)

Financials

Market cap: $38.9K
Total revenue: $0
Enterprise value: $194.7K

Beyond the preview

Go deeper on Himalaya Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Himalaya Therapeutics.

Explore the full profile